Hypertonic Resuscitation Following Traumatic Injury
This study has been terminated.
(Futility & potential safety concern (increased early mortality in the HS/HSD arms for those with no PRBC in 1st 24 hr, post-randomization subgp))
Sponsor:
University of Washington
Collaborators:
The Institute of Circulatory and Respiratory Health (ICRH)
Defence Research and Development Canada
Information provided by:
University of Washington
ClinicalTrials.gov Identifier:
NCT00316017
First received: April 17, 2006
Last updated: February 25, 2011
Last verified: February 2011
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Results First Received: September 2, 2010
| Study Type: | Interventional |
|---|---|
| Study Design: | Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor); Primary Purpose: Treatment |
| Condition: |
Shock, Traumatic |
| Interventions: |
Drug: 7.5% hypertonic saline/6% Dextran-70 (HSD) Drug: 7.5% hypertonic saline (HS) Drug: 0.9% normal saline |
Participant Flow
Recruitment Details
| Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations |
|---|
| Subjects were enrolled by Emergency Medicine Services (EMS) personnel in the pre-hospital setting based on pre-defined inclusion/exclusion criteria. The first subject was enrolled on May 9, 2006 and the last subject was enrolled on August 25, 2008. |
Pre-Assignment Details
| Significant events and approaches for the overall study following participant enrollment, but prior to group assignment |
|---|
| 895 subjects were randomized. 852 subjects completed the study. Randomization was performed when the outer study fluid bag wrapper was removed in the presence of a patient. To ensure there was no bias, a secondary intention to treat analysis was also performed which included all randomized patients even if the fluid was not administered. |
Reporting Groups
| Description | |
|---|---|
| 7.5% Hypertonic Saline/6% Dextran-70 (HSD) | 7.5% hypertonic saline/6% Dextran-70 (HSD) 250 ml |
| 7.5% Hypertonic Saline (HS) | 7.5% hypertonic saline (HS) 250ml dose |
| 0.9% Normal Saline | 0.9% normal saline 250 ml dose as placebo |
Participant Flow: Overall Study
| 7.5% Hypertonic Saline/6% Dextran-70 (HSD) | 7.5% Hypertonic Saline (HS) | 0.9% Normal Saline | |
|---|---|---|---|
| STARTED | 231 [1] | 269 [2] | 395 [3] |
| COMPLETED | 220 | 256 | 376 |
| NOT COMPLETED | 11 | 13 | 19 |
| Protocol Violation | 11 | 13 | 19 |
| [1] | 11 of 11 not completed due to "Bag Opened Not Given" (BONG) |
|---|---|
| [2] | 12 of 13 not completed due to BONG; 1 not completed was a prisoner who was excluded |
| [3] | 19 of 19 not complete due to BONG |
Baseline Characteristics
Reporting Groups
| Description | |
|---|---|
| 7.5% Hypertonic Saline/6% Dextran-70 (HSD) | 7.5% hypertonic saline/6% Dextran-70 (HSD) 250 ml |
| 7.5% Hypertonic Saline (HS) | 7.5% hypertonic saline (HS) 250ml dose |
| 0.9% Normal Saline | 0.9% normal saline 250 ml dose as placebo |
| Total | Total of all reporting groups |
Baseline Measures
| 7.5% Hypertonic Saline/6% Dextran-70 (HSD) | 7.5% Hypertonic Saline (HS) | 0.9% Normal Saline | Total | |
|---|---|---|---|---|
|
Number of Participants
[units: participants] |
220 | 256 | 376 | 852 |
|
Age
[1] [units: participants] |
||||
| <=18 years | 13 | 13 | 23 | 49 |
| Between 18 and 65 years | 188 | 225 | 332 | 745 |
| >=65 years | 18 | 18 | 21 | 57 |
|
Age
[1] [units: years] Mean ± Standard Deviation |
37.7 ± 17.3 | 36.8 ± 16.1 | 36.2 ± 16.4 | 36.7 ± 16.5 |
|
Gender
[2] [units: participants] |
||||
| Female | 50 | 51 | 85 | 186 |
| Male | 170 | 205 | 291 | 666 |
|
Region of Enrollment
[units: participants] |
||||
| United States | 177 | 212 | 283 | 672 |
| Canada | 43 | 44 | 93 | 180 |
| [1] | The HSD group included one subject with no age data available. |
|---|---|
| [2] | Description only includes those subjects who received the study fluid. |
Outcome Measures
| 1. Primary: | 28 Day Survival [ Time Frame: 28 days from time of Emergency Department (ED) arrival ] |
| 2. Secondary: | Adult Respiratory Distress Syndrome(ARDS)-Free Survival Through Day 28 [ Time Frame: 28 days from time of ED arrival ] |
| 3. Secondary: | Worst Multiple Organ Dysfunction Score (MODS) Mean Through Day 28 [ Time Frame: 28 days from time of ED arrival ] |
| 4. Secondary: | Presence of Nosocomial Infection Through Day 28 [ Time Frame: Within 28 days of injury, while hospitalized ] |
| 5. Secondary: | Packed Red Blood Cells (PRBC) First 24 Hours [ Time Frame: First 24 hours from the time of 911 call ] |
| 6. Secondary: | Total Fluids First 24 Hours [ Time Frame: First 24 hours from the time of of 911 call ] |
| 7. Secondary: | Ventilator-free Days Through Day 28 [ Time Frame: Duration of hospital stay through day 28 ] |
| 8. Secondary: | Days Alive Out of the Intensive Care Unit (ICU) Through Day 28 [ Time Frame: First 28 days from the time of 911 call ] |
| 9. Secondary: | Days Alive Out of the Hospital Through Day 28 [ Time Frame: First 28 days from the time of 911 call ] |
| 10. Secondary: | Survival at Hospital Discharge [ Time Frame: Duration of hospital stay through to discharge ] |
| 11. Secondary: | Zero Units PRBC in First 24 Hours [ Time Frame: From the time dispatch received the 911 call to the end of the first 24 hours ] |
| 12. Secondary: | Zero Units PRBC and Died in Field or Emergency Department (ED) [ Time Frame: From the time dispatch received 911 call to the time of death in the field or ED ] |
| 13. Secondary: | Zero Units PRBC and Died Within 6 Hours of Admission to the Hospital [ Time Frame: The first 6 hours from the time of admission to the hospital ] |
| 14. Secondary: | Zero Units PRBC and Died Within 28 Days From the Time of the 911 Call [ Time Frame: From the time dispatch received the 911 call to 28 days ] |
| 15. Secondary: | 1-9 Units PRBC in First 24 Hours [ Time Frame: From the time dispatch received the 911 call to the end of the first 24 hours ] |
| 16. Secondary: | 1-9 Units PRBC and Died in Field or ED [ Time Frame: From the time dispatch received 911 call to the time of death in the field or ED ] |
| 17. Secondary: | 1-9 Units PRBC and Died Within 6 Hours of Admission to the Hospital [ Time Frame: The first 6 hours from the time of admission to the hospital ] |
| 18. Secondary: | 1-9 Units PRBC and Died Within 28 Days From the Time of the 911 Call [ Time Frame: From the time dispatch received the 911 call to 28 days ] |
| 19. Secondary: | Greater Than 10 Units PRBC in First 24 Hours [ Time Frame: From the time dispatch received the 911 call to the end of the first 24 hours ] |
| 20. Secondary: | Greater Than 10 Units PRBC and Died in Field or ED [ Time Frame: From the time dispatch received 911 call to the time of death in the field or ED ] |
| 21. Secondary: | Greater Than 10 Units PRBC and Died Within 6 Hours of Admission to the Hospital [ Time Frame: The first 6 hours from the time of admission to the hospital ] |
| 22. Secondary: | Greater Than 10 Units PRBC and Died Within 28 Days From the Time of the 911 Call [ Time Frame: From the time dispatch received the 911 call to 28 days ] |
More Information
Certain Agreements:
Limitations and Caveats
Results Point of Contact:
Publications of Results:
| Principal Investigators are NOT employed by the organization sponsoring the study. |
| There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. |
Limitations and Caveats
| Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data |
|---|
| The trial was stopped early for futility in the presence of a potential safety concern regarding increased mortality among patients receiving hypertonic solutions and no blood transfusions. This was no longer evident 6 hr after hospital admission. |
Results Point of Contact:
Name/Title: Susanne May, PhD
Organization: Clinical Trial Center, University of Washington, Seattle, WA
phone: 206-685-1302
e-mail: sjmay@uw.edu
Organization: Clinical Trial Center, University of Washington, Seattle, WA
phone: 206-685-1302
e-mail: sjmay@uw.edu
Publications of Results:
| Responsible Party: | Gerald van Belle, PhD/Prinicipal Investigator, Resuscitation Outcomes Consortium Data Coordinating Center |
| ClinicalTrials.gov Identifier: | NCT00316017 History of Changes |
| Other Study ID Numbers: | 28226-A - IND 12506, 5U01HL077863-05, IND #12506 (shock cohort) |
| Study First Received: | April 17, 2006 |
| Results First Received: | September 2, 2010 |
| Last Updated: | February 25, 2011 |
| Health Authority: | United States: Food and Drug Administration United States: Institutional Review Board Canada: Health Canada Canada: Ethics Review Committee |